1. Rodriguez Soriano J, Boichis H, Stark H, Edelmann CM Jr. Proximal renal tubular acidosis. A defect in bicarbonate reabsorption with normal urinary acidification.
Pediatr Res 1967;1:81–98.
2. Haque SK, Ariceta G, Batlle D. Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies.
Nephrol Dial Transplant 2012;27:4273–4287.
3. Moorthi K, Batlle D. Renal tubular acidosis. In: Gennari J, Adrogue HJ, Galla JH, Madias NE, Acid-base disorders and their treatment. Boca Raton: Taylor and Francis; 2005. p. 417–459.
4. Singh AS, Batlle D, Moran-Farias J, Valles P. Inherited proximal and distal renal tubular acidosis.
Scientific american nephrology, dialysis and transplantation. Toronto: Decker; 2017.
5. Batlle D, Haque SK. Genetic causes and mechanisms of distal renal tubular acidosis.
Nephrol Dial Transplant 2012;27:3691–3704.
6. Kurtz I. Renal tubular acidosis: H+/base and ammonia transport abnormalities and clinical syndromes.
Adv Chronic Kidney Dis 2018;25:334–350.
7. Alper SL. Familial renal tubular acidosis.
J Nephrol 2010;23(Suppl 16):S57–S76.
8. Vallés PG, Batlle D. Hypokalemic distal renal tubular acidosis.
Adv Chronic Kidney Dis 2018;25:303–320.
9. Izzedine H, Launay-Vacher V, Isnard-Bagnis C, Deray G. Drug-induced Fanconi’s syndrome.
Am J Kidney Dis 2003;41:292–309.
10. Klootwijk ED, Reichold M, Unwin RJ, Kleta R, Warth R, Bockenhauer D. Renal Fanconi syndrome: taking a proximal look at the nephron.
Nephrol Dial Transplant 2015;30:1456–1460.
11. Foreman JW. Fanconi syndrome.
Pediatr Clin North Am 2019;66:159–167.
12. Sirac C, Bridoux F, Essig M, Devuyst O, Touchard G, Cogné M. Toward understanding renal Fanconi syndrome: step by step advances through experimental models.
Contrib Nephrol 2011;169:247–261.
13. Boron WF. Acid-base transport by the renal proximal tubule.
J Am Soc Nephrol 2006;17:2368–82.
14. Sarker R, Cha B, Kovbasnjuk O, et al. Phosphorylation of NHE3-S719 regulates NHE3 activity through the formation of multiple signaling complexes.
Mol Biol Cell 2017;28:1754–1767.
15. Cotter K, Stransky L, McGuire C, Forgac M. Recent insights into the structure, regulation, and function of the V-ATPases.
Trends Biochem Sci 2015;40:611–622.
16. Purkerson JM, Schwartz GJ. The role of carbonic anhydrases in renal physiology.
Kidney Int 2007;71:103–115.
17. Zhu XL, Sly WS. Carbonic anhydrase IV from human lung. Purification, characterization, and comparison with membrane carbonic anhydrase from human kidney.
J Biol Chem 1990;265:8795–8801.
18. Eladari D, Kumai Y. Renal acid-base regulation: new insights from animal models.
Pflugers Arch 2015;467:1623–1641.
19. Boron WF. Sharpey-Schafer lecture: gas channels.
Exp Physiol 2010;95:1107–1130.
20. Fang X, Yang B, Matthay MA, Verkman AS. Evidence against aquaporin-1-dependent CO2 permeability in lung and kidney.
J Physiol 2002;542(Pt 1):63–69.
21. Hurst TK, Wang D, Thompson RB, Fierke CA. Carbonic anhydrase II-based metal ion sensing: advances and new perspectives.
Biochim Biophys Acta 2010;1804:393–403.
22. Huynh KW, Jiang J, Abuladze N, et al. CryoEM structure of the human SLC4A4 sodium-coupled acid-base transporter NBCe1.
Nat Commun 2018;9:900
23. Kurtz I, Zhu Q. Proximal renal tubular acidosis mediated by mutations in NBCe1-A: unraveling the transporter’s structure-functional properties.
Front Physiol 2013;4:350
24. Warth R, Barrière H, Meneton P, et al. Proximal renal tubular acidosis in TASK2 K+ channel-deficient mice reveals a mechanism for stabilizing bicarbonate transport.
Proc Natl Acad Sci U S A 2004;101:8215–8220.
25. Hamm LL, Simon EE. Roles and mechanisms of urinary buffer excretion.
Am J Physiol 1987;253(4 Pt 2):F595–F605.
26. Alexander RT, Bitzan M. Renal tubular acidosis.
Pediatr Clin North Am 2019;66:135–157.
27. Mount DB. Thick ascending limb of the loop of Henle.
Clin J Am Soc Nephrol 2014;9:1974–1986.
28. Alper SL, Darman RB, Chernova MN, Dahl NK. The AE gene family of Cl/HCO3– exchangers.
J Nephrol 2002;15(Suppl 5):S41–S53.
29. Wagner S, Vogel R, Lietzke R, Koob R, Drenckhahn D. Immunochemical characterization of a band 3-like anion exchanger in collecting duct of human kidney.
Am J Physiol 1987;253(2 Pt 2):F213–F221.
30. Schuster VL. Function and regulation of collecting duct intercalated cells.
Annu Rev Physiol 1993;55:267–288.
31. Alper SL, Natale J, Gluck S, Lodish HF, Brown D. Subtypes of intercalated cells in rat kidney collecting duct defined by antibodies against erythroid band 3 and renal vacuolar H+-ATPase.
Proc Natl Acad Sci U S A 1989;86:5429–5433.
32. Rodríguez Soriano J. Renal tubular acidosis: the clinical entity.
J Am Soc Nephrol 2002;13:2160–2170.
33. Igarashi T, Sekine T, Inatomi J, Seki G. Unraveling the molecular pathogenesis of isolated proximal renal tubular acidosis.
J Am Soc Nephrol 2002;13:2171–2177.
34. Lemann J Jr, Adams ND, Wilz DR, Brenes LG. Acid and mineral balances and bone in familial proximal renal tubular acidosis.
Kidney Int 2000;58:1267–1277.
35. Finer G, Landau D. Clinical approach to proximal renal tubular acidosis in children.
Adv Chronic Kidney Dis 2018;25:351–357.
36. Bolt RJ, Wennink JM, Verbeke JI, Shah GN, Sly WS, Bökenkamp A. Carbonic anhydrase type II deficiency.
Am J Kidney Dis 2005;46:A50e71–e3.
37. Fathallah DM, Bejaoui M, Lepaslier D, Chater K, Sly WS, Dellagi K. Carbonic anhydrase II (CA II) deficiency in Maghrebian patients: evidence for founder effect and genomic recombination at the CA II locus.
Hum Genet 1997;99:634–637.
38. Shah GN, Bonapace G, Hu PY, Strisciuglio P, Sly WS. Carbonic anhydrase II deficiency syndrome (osteopetrosis with renal tubular acidosis and brain calcification): novel mutations in CA2 identified by direct sequencing expand the opportunity for genotype-phenotype correlation.
Hum Mutat 2004;24:272
39. Winum JY, Poulsen SA, Supuran CT. Therapeutic applications of glycosidic carbonic anhydrase inhibitors.
Med Res Rev 2009;29:419–455.
40. Supuran CT, Scozzafava A. Benzolamide is not a membrane-impermeant carbonic anhydrase inhibitor.
J Enzyme Inhib Med Chem 2004;19:269–273.
41. Keilani T, Segal R, Esparaz D, et al. Effect of dorzolamide, a novel topical carbonic anhydrase inhibitor, on urinary acidification in subjects with moderate renal impairment (abstract).
J Investig Med 1995;43(Suppl 2):203A–415A.
42. Magen D, Berger L, Coady MJ, et al. A loss-of-function mutation in NaPi-IIa and renal Fanconi’s syndrome.
N Engl J Med 2010;362:1102–1109.
43. Klootwijk ED, Reichold M, Helip-Wooley A, et al. Mistargeting of peroxisomal EHHADH and inherited renal Fanconi’s syndrome.
N Engl J Med 2014;370:129–138.
44. Hamilton AJ, Bingham C, McDonald TJ, et al. The HNF4A R76W mutation causes atypical dominant Fanconi syndrome in addition to a β cell phenotype.
J Med Genet 2014;51:165–169.
45. Baum M. The Fanconi syndrome of cystinosis: insights into the pathophysiology.
Pediatr Nephrol 1998;12:492–497.
46. Wilmer MJ, Schoeber JP, van den Heuvel LP, Levtchenko EN. Cystinosis: practical tools for diagnosis and treatment.
Pediatr Nephrol 2011;26:205–215.
47. Langman CB, Barshop BA, Deschênes G, et al. Conference Participants. Controversies and research agenda in nephropathic cystinosis: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference.
Kidney Int 2016;89:1192–1203.
48. Bäumner S, Weber LT. Nephropathic cystinosis: symptoms, treatment, and perspectives of a systemic disease.
Front Pediatr 2018;6:58
49. Park MA, Pejovic V, Kerisit KG, Junius S, Thoene JG. Increased apoptosis in cystinotic fibroblasts and renal proximal tubule epithelial cells results from cysteinylation of protein kinase Cdelta.
J Am Soc Nephrol 2006;17:3167–3175.
50. Cherqui S, Courtoy PJ. The renal Fanconi syndrome in cystinosis: pathogenic insights and therapeutic perspectives.
Nat Rev Nephrol 2017;13:115–131.
51. Kumar A, Bachhawat AK. A futile cycle, formed between two ATP-dependant gamma-glutamyl cycle enzymes, gamma-glutamyl cysteine synthetase and 5-oxoprolinase: the cause of cellular ATP depletion in nephrotic cystinosis?
J Biosci 2010;35:21–25.
52. De Matteis MA, Staiano L, Emma F, Devuyst O. The 5-phosphatase OCRL in Lowe syndrome and Dent disease 2.
Nat Rev Nephrol 2017;13:455–470.
53. Loi M. Lowe syndrome.
Orphanet J Rare Dis 2006;1:16
54. Messiaen T, Deret S, Mougenot B, et al. Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients.
Medicine (Baltimore) 2000;79:135–154.
55. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report.
Am J Kidney Dis 2002;40:1331–1333.
56. Earle KE, Seneviratne T, Shaker J, Shoback D. Fanconi’s syndrome in HIV+ adults: report of three cases and literature review.
J Bone Miner Res 2004;19:714–721.
57. Nelson M, Azwa A, Sokwala A, Harania RS, Stebbing J. Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy.
AIDS 2008;22:1374–1376.
58. Crowther MA, Callaghan W, Hodsman AB, Mackie ID. Dideoxyinosine-associated nephrotoxicity.
AIDS 1993;7:131–132.
59. Izzedine H, Launay-Vacher V, Deray G. Fanconi syndrome associated with didanosine therapy.
AIDS 2005;19:844–845.
60. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
Am J Kidney Dis 2011;57:773–780.
61. Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir.
Mol Pharmacol 2007;71:619–627.
62. Sax PE, Wohl D, Yin MT, et al. GS-US-292-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Lancet 2015;385:2606–2615.
63. Bahr NC, Yarlagadda SG. Fanconi syndrome and tenofovir alafenamide: a case report.
Ann Intern Med 2019 Jan 29 [Epub].
64. D’Ythurbide G, Goujard C, Méchaï F, Blanc A, Charpentier B, Snanoudj R. Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: a case report and literature review.
Nephrol Dial Transplant 2007;22:3656–3659.
65. Voûte PA, van den Berg H, Behrendt H, Michiels E, de Kraker J. Ifosfamide in the treatment of pediatric malignancies. Semin Oncol 1996;23(3 Suppl 7):8–11.
66. Bokemeyer C, Harstrick A, Beyer J, et al. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group. Semin Oncol 1998;25(2 Suppl 4):24–32.
67. Rossi R, Pleyer J, Schäfers P, et al. Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients.
Med Pediatr Oncol 1999;32:177–182.
68. Yaseen Z, Michoudet C, Baverel G, Dubourg L. In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro.
Pediatr Nephrol 2008;23:611–618.
69. Skinner R, Sharkey IM, Pearson AD, Craft AW. Ifosfamide, mesna, and nephrotoxicity in children.
J Clin Oncol 1993;11:173–190.
70. Loebstein R, Atanackovic G, Bishai R, et al. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.
J Clin Pharmacol 1999;39:454–461.
71. Oberlin O, Fawaz O, Rey A, et al. Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
J Clin Oncol 2009;27:5350–5355.
72. Stöhr W, Paulides M, Bielack S, et al. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.
Pediatr Blood Cancer 2007;48:447–452.
73. Negro A, Regolisti G, Perazzoli F, Davoli S, Sani C, Rossi E. Ifosfamide-induced renal Fanconi syndrome with associated nephrogenic diabetes insipidus in an adult patient.
Nephrol Dial Transplant 1998;13:1547–1549.
74. Beckwith C, Flaharty KK, Cheung AK, Beatty PG. Fanconi’s syndrome due to ifosfamide. Bone Marrow Transplant 1993;11:71–73.
75. Farry JK, Flombaum CD, Latcha S. Long term renal toxicity of ifosfamide in adult patients--5 year data.
Eur J Cancer 2012;48:1326–1331.
76. Nissim I, Horyn O, Daikhin Y, et al. Ifosfamide-induced nephrotoxicity: mechanism and prevention.
Cancer Res 2006;66:7824–7831.
77. Yaseen Z, Michoudet C, Baverel G, Dubourg L. Mechanisms of the ifosfamide-induced inhibition of endocytosis in the rat proximal kidney tubule.
Arch Toxicol 2008;82:607–614.
78. Linch M, Cunningham D, Mingo O, Stiles A, Farquhar-Smith WP. Renal tubular acidosis due to oxaliplatin.
Ann Oncol 2007;18:805–806.
79. Negro A, Grasselli C, Galli P. Oxaliplatin-induced proximal renal tubular acidosis.
Intern Emerg Med 2010;5:267–268.
80. Cachat F, Nenadov-Beck M, Guignard JP. Occurrence of an acute Fanconi syndrome following cisplatin chemotherapy.
Med Pediatr Oncol 1998;31:40–41.
81. Portilla D, Li S, Nagothu KK, et al. Metabolomic study of cisplatin-induced nephrotoxicity.
Kidney Int 2006;69:2194–2204.
82. Nagothu KK, Bhatt R, Kaushal GP, Portilla D. Fibrate prevents cisplatin-induced proximal tubule cell death.
Kidney Int 2005;68:2680–2693.
83. Mirza N, Marson AG, Pirmohamed M. Effect of topiramate on acid-base balance: extent, mechanism and effects.
Br J Clin Pharmacol 2009;68:655–661.
84. Ozer Y, Altunkaya H. Topiramate induced metabolic acidosis.
Anaesthesia 2004;59:830
85. Philippi H, Boor R, Reitter B. Topiramate and metabolic acidosis in infants and toddlers.
Epilepsia 2002;43:744–747.
86. Sacré A, Jouret F, Manicourt D, Devuyst O. Topiramate induces type 3 renal tubular acidosis by inhibiting renal carbonic anhydrase.
Nephrol Dial Transplant 2006;21:2995–2996.
87. Recacha R, Costanzo MJ, Maryanoff BE, Chattopadhyay D. Crystal structure of human carbonic anhydrase II complexed with an anti-convulsant sugar sulphamate.
Biochem J 2002;361(Pt 3):437–441.
88. Maryanoff BE, McComsey DF, Costanzo MJ, Hochman C, Smith-Swintosky V, Shank RP. Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform.
J Med Chem 2005;48:1941–1947.
89. Knorr M, Schaper J, Harjes M, Mayatepek E, Rosenbaum T. Fanconi syndrome caused by antiepileptic therapy with valproic Acid.
Epilepsia 2004;45:868–871.
90. Endo A, Fujita Y, Fuchigami T, Takahashi S, Mugishima H. Fanconi syndrome caused by valproic acid.
Pediatr Neurol 2010;42:287–290.
91. Shiari R, Bagherzade L, Alaei MR. Fanconi syndrome associated with valporic Acid: a case report.
Iran Red Crescent Med J 2011;13:844–845.
92. Hawkins E, Brewer E. Renal toxicity induced by valproic acid (Depakene).
Pediatr Pathol 1993;13:863–868.
93. Lenoir GR, Perignon JL, Gubler MC, Broyer M. Valproic acid: a possible cause of proximal tubular renal syndrome.
J Pediatr 1981;98:503–504.
94. Al-Bander HA, Weiss RA, Humphreys MH, Morris RC Jr. Dysfunction of the proximal tubule underlies maleic acid-induced type II renal tubular acidosis.
Am J Physiol 1982;243:F604–F611.
95. Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
Transfusion 2007;47:1919–1929.
96. Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Niño MD, Villarrubia J, Ortiz A. Deferasirox nephrotoxicity-the knowns and unknowns.
Nat Rev Nephrol 2014;10:574–586.
97. Grangé S, Bertrand DM, Guerrot D, Eas F, Godin M. Acute renal failure and Fanconi syndrome due to deferasirox.
Nephrol Dial Transplant 2010;25:2376–2378.
98. Rafat C, Fakhouri F, Ribeil JA, Delarue R, Le Quintrec M. Fanconi syndrome due to deferasirox.
Am J Kidney Dis 2009;54:931–934.
99. Papneja K, Bhatt MD, Kirby-Allen M, Arora S, Wiernikowski JT, Athale UH. Fanconi syndrome secondary to deferasirox in Diamond-Blackfan anemia: case series and recommendations for early diagnosis.
Pediatr Blood Cancer 2016;63:1480–1483.
100. Chuang GT, Tsai IJ, Tsau YK, Lu MY. Transfusion-dependent thalassaemic patients with renal Fanconi syndrome due to deferasirox use.
Nephrology (Carlton) 2015;20:931–935.
101. Lenz EM, Bright J, Knight R, et al. Metabonomics with 1H-NMR spectroscopy and liquid chromatography-mass spectrometry applied to the investigation of metabolic changes caused by gentamicin-induced nephrotoxicity in the rat.
Biomarkers 2005;10:173–187.
102. Ghiculescu RA, Kubler PA. Aminoglycoside-associated Fanconi syndrome.
Am J Kidney Dis 2006;48:e89–e93.
103. Gainza FJ, Minguela JI, Lampreabe I. Aminoglycoside-associated Fanconi’s syndrome: an underrecognized entity.
Nephron 1997;77:205–211.
104. Melnick JZ, Baum M, Thompson JR. Aminoglycoside-induced Fanconi’s syndrome.
Am J Kidney Dis 1994;23:118–122.
105. Russo JC, Adelman RD. Gentamicin-induced Fanconi syndrome.
J Pediatr 1980;96:151–153.
106. Fleck C, Schwertfeger M, Taylor PM. Regulation of renal amino acid (AA) transport by hormones, drugs and xenobiotics-a review.
Amino Acids 2003;24:347–374.
107. Batlle D, Hays S, Foley R, Chan Y, Arruda JA, Kurtzman NA. Proximal renal tubular acidosis and hypophosphatemia induced by arginine.
Adv Exp Med Biol 1982;151:239–249.
108. Lo JC, Chertow GM, Rennke H, Seifter JL. Fanconi’s syndrome and tubulointerstitial nephritis in association with L-lysine ingestion.
Am J Kidney Dis 1996;28:614–617.
109. Benninga MA, Lilien M, de Koning TJ, et al. Renal Fanconi syndrome with ultrastructural defects in lysinuric protein intolerance.
J Inherit Metab Dis 2007;30:402–403.
110. Riccio E, Pisani A. Fanconi syndrome with lysinuric protein intolerance.
Clin Kidney J 2014;7:599–601.
111. Perheentupa J, Visakorpi JK. Protein intolerance with deficient transport of basic aminoacids. Another inborn error of metabolism.
Lancet 1965;2:813–816.
112. Carpenter TO, Levy HL, Holtrop ME, Shih VE, Anast CS. Lysinuric protein intolerance presenting as childhood osteoporosis. Clinical and skeletal response to citrulline therapy.
N Engl J Med 1985;312:290–294.
113. DiRocco M, Garibotto G, Rossi GA, et al. Role of haematological, pulmonary and renal complications in the long-term prognosis of patients with lysinuric protein intolerance.
Eur J Pediatr 1993;152:437–440.
114. Parto K, Kallajoki M, Aho H, Simell O. Pulmonary alveolar proteinosis and glomerulonephritis in lysinuric protein intolerance: case reports and autopsy findings of four pediatric patients.
Hum Pathol 1994;25:400–407.
115. Houten SM, Te Brinke H, Denis S, et al. Genetic basis of hyperlysinemia.
Orphanet J Rare Dis 2013;8:57
116. Perrone D, Afridi F, King-Morris K, Komarla A, Kar P. Proximal renal tubular acidosis (Fanconi syndrome) induced by apremilast: a case report.
Am J Kidney Dis 2017;70:729–731.
117. Barbier O, Jacquillet G, Tauc M, Cougnon M, Poujeol P. Effect of heavy metals on, and handling by, the kidney.
Nephron Physiol 2005;99:p105–p110.
118. García Rodríguez JF, Sánchez-Guisande D, Novoa D, Romero R, Arcocha V. Fanconi syndrome caused by mercury chloride poisoning. Rev Clin Esp 1989 184:111–112. Spanish.
119. Johri N, Jacquillet G, Unwin R. Heavy metal poisoning: the effects of cadmium on the kidney.
Biometals 2010;23:783–792.
120. Gonick HC. Nephrotoxicity of cadmium & lead.
Indian J Med Res 2008;128:335–352.
121. Rochman J, Lichtig C, Osterweill D, Tatarsky I, Eidelman S. ASdult Fanconi’s syndrome with renal tubular acidosis in association with renal amyloidosis: occurrence in a patient with chronic lymphocytic leukemia.
Arch Intern Med 1980;140:1361–1363.
122. Riley AL, Ryan LM, Roth DA. Renal proximal tubular dysfunction and paroxysmal nocturnal hemoglobinuria.
Am J Med 1977;62:125–129.
123. Irizarry-Alvarado JM, Dwyer JP, Brumble LM, Alvarez S, Mendez JC. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases.
AIDS Read 2009;19:114–121.
124. Luciani A, Sirac C, Terryn S, et al. Impaired lysosomal function underlies monoclonal light chain-associated renal Fanconi syndrome.
J Am Soc Nephrol 2016;27:2049–2061.
125. Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity.
HIV Med 2009;10:482–487.
126. Batlle DC, Hizon M, Cohen E, Gutterman C, Gupta R. The use of the urinary anion gap in the diagnosis of hyperchloremic metabolic acidosis.
N Engl J Med 1988;318:594–599.
127. Batlle D, Ba Aqeel SH, Marquez A. The urine anion gap in context.
Clin J Am Soc Nephrol 2018;13:195–197.
128. Kim GH, Han JS, Kim YS, Joo KW, Kim S, Lee JS. Evaluation of urine acidification by urine anion gap and urine osmolal gap in chronic metabolic acidosis.
Am J Kidney Dis 1996;27:42–47.
129. Norden AG, Lapsley M, Unwin RJ. Urine retinol-binding protein 4: a functional biomarker of the proximal renal tubule.
Adv Clin Chem 2014;63:85–122.
130. Hall AM, Bass P, Unwin RJ. Drug-induced renal Fanconi syndrome.
QJM 2014;107:261–269.